Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -38.70
- Piotroski Score 2.00
- Grade Outperform
- Symbol (NVIV)
- Company InVivo Therapeutics Holdings Corp.
- Price $0.32
- Changes Percentage (-34.28%)
- Change -$0.17
- Day Low $0.30
- Day High $0.41
- Year High $2.40
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.28
- Trailing P/E Ratio -0.097774390243902
- Forward P/E Ratio -0.097774390243902
- P/E Growth -0.097774390243902
- Net Income $-10,179,000
Income Statement
Quarterly
Annual
Latest News of NVIV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Italian town joins mayor on walks to lose weight blamed on his 'convivial obligations'
Luciano Fregonese, mayor of Valdobbiadene, Italy, aims to lose weight gained during his tenure by taking weekly walks with locals. His weight gain was due to job demands and eating habits....
By The Guardian | 3 months ago -
Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future
Invivyd, Inc., a biopharmaceutical company, is nearing a breakthrough with a predicted breakeven in 2025. Analysts forecast a profit of US$58m in 2026, requiring a 70% annual growth rate....
By Yahoo! Finance | 4 months ago
